Dr Jon Court, Syntaxin’s Chief Development Officer, has over 30 years of pharmaceutical research and development experience. Dr Court has held R&D roles with Wellcome and Roche and was the founder and CEO of Fulcrum Pharma plc, a global contract drug development business engaged in global NCE and NBE development.
Syntaxin’s Chief Medical Officer, Dr Richard Jones, has over 25 years of global pharmaceutical industry experience with an extensive background in all stages of drug development and regulatory affairs. Dr Jones held senior medical and regulatory roles at Johnson & Johnson, Hoffman-La Roche and Aspreva Pharmaceuticals.
In addition to Syntaxin’s internal expertise, Syntaxin has a broad network of expert Scientific advisors and Key Opinion Leaders (KOLs) which support concept development, clinical trial design and execution.
Syntaxin has adopted robust project management and outsourcing practices to benefit from research, preclinical, CMC and clinical development expertise through contractual partnering. This is led by highly experienced qualified staff, leveraged by consultants that identify, audit, select and contract with partner organisations.
Syntaxin partners with both academic centres of excellence and commercial CROs/CMOs, adopting similar high standards in audit, selection, contract and alliance management processes for all partners.
Syntaxin’s focus on targeted cell secretion inhibitors offers a rapid approach to delivering clinical efficacy in diseases where the secretion is tightly coupled to the clinical pathophysiology. Building on the success of our pain collaboration with Allergan, our development programme in Acromegaly leads this concept through inhibition of growth hormone release and normalization of IGF-1 levels (driven though GH stimulation) and offers an additional opportunity to extend the indication into other IGF-1 related disorders including metabolic disease and cancer.
Our entry-into-man trial directly into Acromegaly patients by the systemic route will address tolerability and safety while defining the dose interval and minimal effective clinical dose for clinical efficacy for this novel platform in an orphan drug indication with high unmet medical need.